Literature DB >> 21412094

Magnetic resonance imaging of prostate cancer: diffusion-weighted imaging in comparison with sextant biopsy.

Jin Yamamura1, Georg Salomon, Ralph Buchert, Arne Hohenstein, Joachim Graessner, Hartwig Huland, Markus Graefen, Gerhard Adam, Ulrike Wedegaertner.   

Abstract

PURPOSE: To retrospectively evaluate the impact of diffusion-weighted imaging (DWI) on the detection of prostate cancer in comparison with sextant biopsy.
MATERIALS AND METHODS: Fifty patients with clinical suspicion of prostate cancer underwent a combined endorectal-body-phased array magnetic resonance imaging examination at a 1.5 T magnetic resonance imaging (Siemens, Erlangen, Germany). The DWI was performed using b values of 50, 400, 800 s/mm. The prostate was divided into sextants, including the apex, the middle aspect, and the base for the left and right sides, separately. Regions of interest were placed in the peripheral zone of each sextant to evaluate the apparent diffusion coefficient (ADC) values. The results of the DWI were compared side by side with the findings of the histological examination of endorectal sonographically guided sextant biopsy. The sensitivity and specificity of ADC for the identification of the tumor tissue were computed for variable discrimination thresholds to evaluate its receiver operating characteristic. An association between ADC and Gleason score was tested for both the whole study group and on an individual basis using the nonparametric Spearman ρ test and the Pearson correlation, respectively.
RESULTS: Histopathology identified tumor tissue in 21 (42%) of the 50 patients. The ADC value was 1.65 ± 0.32 mm/s 10 in normal tissue and 0.96 ± 0.24 mm/s 10 in tumor tissue (mean ± 1 SD). The area under the receiver operating characteristic curve was 0.966. Using the discrimination threshold 1.21 mm/s 10, for example, the ADC value provided a sensitivity of 0.92 and a specificity of 0.93. There was a highly significant negative correlation between the ADC value and the Gleason score in the tumor-positive tissue probes (n = 62, ρ = -0.405, P = 0.001) in the whole study group. On the individual patient basis, the Pearson correlation revealed a mean coefficient of r = -0.89 (SD ± 0.12) with a P < 0.001.
CONCLUSIONS: Diffusion-weighted imaging of the prostate can be used to differentiate benign from malignant tissue in the peripheral zone. In the present study, ADC values were significantly lower in prostate cancer than in benign tissue.

Entities:  

Mesh:

Year:  2011        PMID: 21412094     DOI: 10.1097/RCT.0b013e3181fc5409

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  15 in total

1.  Prostate cancer diagnostics: innovative imaging in case of multiple negative biopsies.

Authors:  Tillmann Loch
Journal:  World J Urol       Date:  2011-07-09       Impact factor: 4.226

2.  Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma.

Authors:  Joe H Chang; Daryl Lim Joon; Sze Ting Lee; Chee-Yan Hiew; Stephen Esler; Sylvia J Gong; Morikatsu Wada; David Clouston; Richard O'Sullivan; Yin P Goh; Henri Tochon-Danguy; J Gordon Chan; Damien Bolton; Andrew M Scott; Vincent Khoo; Ian D Davis
Journal:  Eur Radiol       Date:  2013-11-06       Impact factor: 5.315

3.  Novel PCA-VIP scheme for ranking MRI protocols and identifying computer-extracted MRI measurements associated with central gland and peripheral zone prostate tumors.

Authors:  Shoshana B Ginsburg; Satish E Viswanath; B Nicolas Bloch; Neil M Rofsky; Elizabeth M Genega; Robert E Lenkinski; Anant Madabhushi
Journal:  J Magn Reson Imaging       Date:  2014-06-18       Impact factor: 4.813

Review 4.  Economic Benefits and Diagnostic Quality of Diffusion-Weighted Magnetic Resonance Imaging for Primary Lung Cancer.

Authors:  Katsuo Usuda; Aika Funazaki; Ryo Maeda; Atsushi Sekimura; Nozomu Motono; Munetaka Matoba; Hidetaka Uramoto
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-10-04       Impact factor: 1.520

5.  Multivariate modelling of prostate cancer combining magnetic resonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters.

Authors:  S F Riches; G S Payne; V A Morgan; D Dearnaley; S Morgan; M Partridge; N Livni; C Ogden; N M deSouza
Journal:  Eur Radiol       Date:  2015-03-07       Impact factor: 5.315

6.  Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer.

Authors:  Rajakumar Nagarajan; Daniel Margolis; Steven Raman; Ke Sheng; Christopher King; Robert Reiter; M Albert Thomas
Journal:  Adv Urol       Date:  2011-12-15

Review 7.  The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis.

Authors:  Chen Jie; Liu Rongbo; Tan Ping
Journal:  Eur Radiol       Date:  2014-05-28       Impact factor: 5.315

8.  How to Discriminate Lung Cancer From Benign Pulmonary Nodules and Masses? Usefulness of Diffusion-Weighted Magnetic Resonance Imaging With Apparent Diffusion Coefficient and Inside/Wall Apparent Diffusion Coefficient Ratio.

Authors:  Katsuo Usuda; Shun Iwai; Aika Yamagata; Yoshihito Iijima; Nozomu Motono; Mariko Doai; Munetaka Matoba; Keiya Hirata; Hidetaka Uramoto
Journal:  Clin Med Insights Oncol       Date:  2021-07-07

9.  Diffusion-weighted magnetic resonance diagnosis of local recurrences of prostate cancer after radical prostatectomy: preliminary evaluation on twenty-seven cases.

Authors:  Salvatore Francesco Carbone; Luigi Pirtoli; Veronica Ricci; Tommaso Carfagno; Paolo Tini; Augusto La Penna; Eleonora Cacchiarelli; Luca Volterrani
Journal:  Biomed Res Int       Date:  2014-02-16       Impact factor: 3.411

10.  Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness.

Authors:  Andrei Lebovici; Silviu A Sfrangeu; Diana Feier; Cosmin Caraiani; Ciprian Lucan; Mihai Suciu; Florin Elec; Gheorghita Iacob; Mircea Buruian
Journal:  BMC Med Imaging       Date:  2014-05-10       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.